| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ann M Mortime. Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatric disease and treatment. vol 5. 2011-04-26. PMID:19557121. |
amisulpride is efficacious, effective and well tolerated in positive symptoms of schizophrenia: there is extensive evidence that it treats negative symptoms when given in low doses, although relative lack of eps and an antidepressant effect may contribute. |
2011-04-26 |
2023-08-12 |
Not clear |
| D N Mendhekar, D Lohia, P Katari. Tardive oculogyric crisis associated with amisulpride monotherapy. Journal of postgraduate medicine. vol 56. issue 4. 2010-11-15. PMID:20935407. |
we report a case of a young woman with schizophrenia who presented with tardive ogc related to amisulpride. |
2010-11-15 |
2023-08-12 |
Not clear |
| Norbert Müller, Daniela Krause, Sandra Dehning, Richard Musil, Rebecca Schennach-Wolff, Michael Obermeier, Hans-Jürgen Möller, Volker Klauss, Markus J Schwarz, Michael Riede. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophrenia research. vol 121. issue 1-3. 2010-11-08. PMID:20570110. |
celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. |
2010-11-08 |
2023-08-12 |
Not clear |
| Norbert Müller, Daniela Krause, Sandra Dehning, Richard Musil, Rebecca Schennach-Wolff, Michael Obermeier, Hans-Jürgen Möller, Volker Klauss, Markus J Schwarz, Michael Riede. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophrenia research. vol 121. issue 1-3. 2010-11-08. PMID:20570110. |
taking these findings into account, we conducted a double-blind, placebo-controlled, randomized trial of celecoxib augmentation to amisulpride treatment in patients with a first manifestation of schizophrenia. |
2010-11-08 |
2023-08-12 |
Not clear |
| Artemios Pehlivanidis, Areti C Spyropoulou, Athanasios Tourkantonis, George N Papadimitrio. Amisulpride monotherapy in a patient with clozapine-resistant schizophrenia. Clinical neuropharmacology. vol 33. issue 3. 2010-08-31. PMID:20502137. |
amisulpride monotherapy in a patient with clozapine-resistant schizophrenia. |
2010-08-31 |
2023-08-12 |
Not clear |
| Philippe Nuss, Cedric Tessie. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride. Current medical research and opinion. vol 26. issue 4. 2010-06-16. PMID:20121655. |
antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride. |
2010-06-16 |
2023-08-12 |
Not clear |
| Anna Dietrich-Muszalska, Beata Ola. Inhibitory effects of polyphenol compounds on lipid peroxidation caused by antipsychotics (haloperidol and amisulpride) in human plasma in vitro. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 11. issue 2 Pt 2. 2010-06-14. PMID:19225991. |
since oxidative stress observed in schizophrenia may be caused partially by the treatment of patients with various antipsychotics, the aim of the study was to assess whether there is a difference between a first-generation antipsychotic (fga; haloperidol) and a second-generation antipsychotic (sga; amisulpride (4-amino-n-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethysufonyl-2-methoxy-benzamide)) action on peroxidation of plasma lipids, and to establish the effects of polyphenol compounds (resveratrol (3,4',5-trihydroxystilbene) and quercetin (3,5,7,3',4'- pentahydroxyflavone)) and the antipsychotics action on this process in vitro. |
2010-06-14 |
2023-08-12 |
human |
| Emmanouil N Rizos, Athanasia Papadopoulou, Efstathios Laskos, Panagiota G Michalopoulou, Anastasia Kastania, Dimitrios Vasilopoulos, Konstantinos Katsafouros, Lefteris Lykoura. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 11. issue 2 Pt 2. 2010-06-14. PMID:20218789. |
we measured serum bdnf levels in 47 patients with schizophrenia during a relapse and again 6 weeks after administration of antipsychotic treatment (14 on risperidone, 18 on haloperidol, 10 on olanzapine and five on amisulpride) and in 44 healthy volunteers. |
2010-06-14 |
2023-08-12 |
human |
| Subhrojyoti Bhowmick, Avijit Hazra, Malati Ghos. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. The Australian and New Zealand journal of psychiatry. vol 44. issue 3. 2010-06-02. PMID:20050717. |
amisulpride versus olanzapine in the treatment of schizophrenia in indian patients: randomized controlled trial. |
2010-06-02 |
2023-08-12 |
Not clear |
| Subhrojyoti Bhowmick, Avijit Hazra, Malati Ghos. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. The Australian and New Zealand journal of psychiatry. vol 44. issue 3. 2010-06-02. PMID:20050717. |
amisulpride, a new atypical antipsychotic, is reported to be effective for both positive and negative symptoms of schizophrenia in western countries but indian experience is limited. |
2010-06-02 |
2023-08-12 |
Not clear |
| Subhrojyoti Bhowmick, Avijit Hazra, Malati Ghos. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. The Australian and New Zealand journal of psychiatry. vol 44. issue 3. 2010-06-02. PMID:20050717. |
the aim of the present study was therefore to conduct a trial of amisulpride versus olanzapine in indian schizophrenia patients. |
2010-06-02 |
2023-08-12 |
Not clear |
| Constantin Psarros, Christos G Theleritis, Thomas J Paparrigopoulos, Antonios M Politis, George N Papadimitrio. Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis. International journal of geriatric psychiatry. vol 24. issue 5. 2010-05-26. PMID:19072747. |
the objective of the present study was to evaluate the efficacy and safety of amisulpride monotherapy in a diagnostically homogeneous group of elderly patients without cognitive impairment suffering from very-late-onset schizophrenia. |
2010-05-26 |
2023-08-12 |
Not clear |
| Katja Komossa, Christine Rummel-Kluge, Heike Hunger, Franziska Schmid, Sandra Schwarz, Joaquim I Silveira da Mota Neto, Werner Kissling, Stefan Leuch. Amisulpride versus other atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews. issue 1. 2010-04-16. PMID:20091599. |
amisulpride versus other atypical antipsychotics for schizophrenia. |
2010-04-16 |
2023-08-12 |
Not clear |
| Fatma Varol Tas, Taner Guveni. Amisulpride treatment of adolescent patients with schizophrenia or schizo-affective disorders. European child & adolescent psychiatry. vol 18. issue 8. 2010-02-19. PMID:19267176. |
amisulpride treatment of adolescent patients with schizophrenia or schizo-affective disorders. |
2010-02-19 |
2023-08-12 |
Not clear |
| M Lambert, B G Schimmelmann, D Naber, F-X Eich, H Schulz, C G Huber, A Karo. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry. vol 42. issue 6. 2010-02-01. PMID:19924588. |
early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. |
2010-02-01 |
2023-08-12 |
Not clear |
| C Akkaya, B Kaya, Z Kotan, A Sarandol, C Ersoy, S Kirl. Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases. Journal of psychopharmacology (Oxford, England). vol 23. issue 6. 2009-09-22. PMID:18562408. |
to our knowledge, this is the first series of cases showing a possible relation between pituitary adenomas and amisulpride treatment in patients with schizophrenia. |
2009-09-22 |
2023-08-12 |
Not clear |
| Samuel Suk-Hyun Hwang, Jae Seung Chang, Kyu Young Lee, Se Hyun Kim, Yong Min Ahn, Yong Sik Ki. Causal model of insight and psychopathology based on the PANSS factors: 1-year cross-sectional and longitudinal revalidation. International clinical psychopharmacology. vol 24. issue 4. 2009-09-15. PMID:19521247. |
this study presents results of a 1-year follow-up investigation of the causal model of insight in schizophrenia using a subsample of acute patients starting or switching to amisulpride included in an earlier study. |
2009-09-15 |
2023-08-12 |
Not clear |
| Juan D Molina, Iván Lerma-Carrillo, Marta Leonor, Fernando Pascual, Hilario Blasco-Fontecilla, Silvia González-Parra, Francisco López-Muñoz, Cecilio Alam. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study. Clinical neuropharmacology. vol 32. issue 1. 2009-09-02. PMID:18978498. |
combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study. |
2009-09-02 |
2023-08-12 |
Not clear |
| Juan D Molina, Iván Lerma-Carrillo, Marta Leonor, Fernando Pascual, Hilario Blasco-Fontecilla, Silvia González-Parra, Francisco López-Muñoz, Cecilio Alam. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study. Clinical neuropharmacology. vol 32. issue 1. 2009-09-02. PMID:18978498. |
the objective of this study is to describe polypharmacy with antipsychotic regimen in patients with schizophrenia discharged with amisulpride from the short-term hospitalization unit. |
2009-09-02 |
2023-08-12 |
Not clear |
| Atheir I Abbas, Peter B Hedlund, Xi-Ping Huang, Thuy B Tran, Herbert Y Meltzer, Bryan L Rot. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology. vol 205. issue 1. 2009-09-02. PMID:19337725. |
amisulpride is approved for clinical use in treating schizophrenia in a number of european countries and also for treating dysthymia, a mild form of depression, in italy. |
2009-09-02 |
2023-08-12 |
Not clear |